![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
M Yamazaki, N Matsuoka, N Maeda, Y Ohkubo and I Yamaguchi
Tsukuba Research Laboratories, Fujisawa Pharmaceutical Co., Ltd., Ibaraki, Japan.
With passive avoidance (PA), Morris water maze (WM) and eight-arm radial maze tasks, we evaluated the memory-enhancing action of FK960 [N- (4-acetyl-1-piperazinyl)-p-fluorobenzamide monohydrate], a compound which we have found through rational drug screening based on our hypothesis that penile erection is a valid predictor of central cholinergic activation. Memory performance in the tasks was impaired in aged (24- to 26-months-old) rats as well as in rats with nucleus basalis magnocellularis lesions. Scopolamine (1 mg/kg i.p.) treatment induced memory impairment in PA and WM; treatment with cysteamine (200 mg/kg s.c.) induced memory impairment in PA but not in WM, whereas fimbria fornix lesioning affected the rats in the opposite manner. FK960 (0.1-10 mg/kg i.p.) ameliorated all the memory impairments except those induced by cysteamine or fimbria fornix lesion, and the dose- response curves were bell shaped with maximal response at 1 to 3.2 mg/kg. The effects of FK960 on the scopolamine-induced memory impairment in the PA and/or WM were abolished by cysteamine (200 mg/kg s.c.), dl-p-chlorophenylalanine methyl ester hydrochloride (150 mg/kg i.p. for 3 days) or raphe lesioning, but not by neonatal 6- hydroxydopamine (35 micrograms/head) treatment. Neurochemical analysis revealed that cysteamine and raphe lesions reduced brain somatostatin and serotonin contents, respectively. The treatment with FK960 (0.32- 320 mg/kg p.o.) dose-dependently increased both serotonin and 5- hydroxyindoleacetic acid levels in the brain areas examined and significantly increased hippocampal somatostatin contents at the smaller doses. From these results, we conclude that FK960 ameliorates cognitive dysfunction through an activation of the somatostatinergic- serotonergic link.
This article has been cited by other articles:
|
|
 |
|
  F. Wang, N. Matsuoka, S. Mutoh, and S. Kaneko Modulation of Ca2+Channel Currents by a Novel Antidementia DrugN-(4-Acetyl-1-piperazinyl)-p-fluorobenzamide Monohydrate (FK960) in Rat Hippocampal Neurons J. Pharmacol. Exp. Ther., January 1, 2004; 308(1): 120 - 126. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Noda, H. Takamatsu, N. Matsuoka, S. Koyama, H. Tsukada, and S. Nishimura Effect of N-(4-Acetyl-1-piperazinyl)-p-fluorobenzamide Monohydrate (FK960), an Antidementia Drug with a Novel Mechanism of Action, on Regional Cerebral Blood Flow and Glucose Metabolism in Aged Rhesus Macaques Studied with Positron Emission Tomography J. Pharmacol. Exp. Ther., July 1, 2003; 306(1): 213 - 217. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Noda, H. Takamatsu, Y. Murakami, K. Yajima, M. Tatsumi, R. Ichise, and S. Nishimura Measurement of Brain Concentration of FK960 for Development of a Novel Antidementia Drug: A PET Study in Conscious Rhesus Monkeys J. Nucl. Med., January 1, 2003; 44(1): 105 - 108. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. P. Hodgkiss and J. S. Kelly Effect of FK960, a Putative Cognitive Enhancer, on Synaptic Transmission in CA1 Neurons of Rat Hippocampus J. Pharmacol. Exp. Ther., April 12, 2001; 297(2): 620 - 628. [Abstract] [Full Text]
|
|
|
|
|
|
N. Matsuoka and T. G. Aigner FK960 [N-(4-Acetyl-1-piperazinyl)-p-fluorobenzamide Monohydrate], a Novel Potential Antidementia Drug, Improves Visual Recognition Memory in Rhesus Monkeys: Comparison with Physostigmine J. Pharmacol. Exp. Ther., March 1, 1997; 280(3): 1201 - 1209. [Abstract] [Full Text]
|
|
 |
 |
 |
|
 |
 |
 |
